In 2026, the word "genetics" has become a marketing term almost as often as a technical one. Several major producers have launched new brands built around proprietary cultivar libraries this year, and procurement teams are left trying to separate documented phenotype work from packaging copy. For Licensed Producers, importers, and pharmacy distributors sourcing dried flower, the distinction matters. Phenotype selection drives cannabinoid consistency, terpene retention, and batch-to-batch reliability long before a flower ever reaches a lab report.
Here is what cultivar and phenotype selection actually involves, the evaluation criteria a B2B buyer should request from any supplier, and the questions that separate genuine genetics programs from marketing language. If you can't get straight answers to those questions, that's a sourcing risk worth flagging before you sign.
What phenotype selection actually means
A cultivar is a named genetic line. A phenotype is how an individual plant from that line expresses itself under a given set of growing conditions: cannabinoid ratio, terpene profile, bud structure, and yield. Two plants grown from the same seed stock can express noticeably different chemistry. Phenotype selection is the process of growing out multiple plants from a cultivar, testing them, and keeping only the individual expressions that meet a defined standard.
For a B2B buyer, this matters because a supplier who has done real phenotype work can tell you, in specific terms, why a given lot looks the way it does. Vague answers are a signal. A supplier relying purely on a brand name usually cannot answer with that level of detail.
Why this affects what you receive as a buyer
Cultivar names travel faster than the underlying genetics. The same name can sit on noticeably different chemistry depending on which producer grew it and which phenotype they selected. Our Ice Cream Cake strain profile is one example of what a documented, single-phenotype specification looks like in practice. A buyer evaluating supply should treat the cultivar name as a starting point for questions, not as a specification.
The genetics evaluation framework: 4 questions for any supplier
Before signing a supply agreement that references "premium genetics" or a named cultivar library, a B2B buyer should be able to get a direct answer to each of the following.
| Question | What a credible answer looks like |
|---|---|
| Where did this phenotype come from? | A documented selection history: number of phenotypes trialled, selection criteria used, and how long the line has been stabilised. |
| How is genetic consistency maintained across grow cycles? | A clear propagation method (tissue culture, mother plant program, or clone lineage) with records tying current stock back to the selected phenotype. |
| What cannabinoid and terpene range should I expect, and how much does it vary by batch? | A stated range, not a single headline figure, supported by Certificate of Analysis data across multiple harvests. |
| Who verifies the testing? | An ISO/IEC 17025 accredited lab, with batch-level traceability back to the harvest and grow room. |
A supplier who answers all four with specifics, rather than brand language, has a genetics program a buyer can underwrite supply decisions on. Cross-checking those answers against the supplier's Certificate of Analysis documentation is the fastest way to confirm the claims hold up.
Terpene and cannabinoid stability across batches
The single biggest gap between a marketed cultivar and a procurement-grade one is batch stability. A phenotype that tests well once in a single harvest is not the same as a phenotype that holds steady over time. Real stability means a consistent cannabinoid and terpene profile across a full cultivation cycle, season after season.
Stability depends on three controllable factors: propagation method, grow room consistency, and post-harvest handling. Tissue culture or verified mother plant propagation keeps the genetic line consistent. Climate controlled indoor cultivation reduces the seasonal swings that affect outdoor or greenhouse production. Hand trimming and controlled drying reduce mechanical degradation of trichomes, which protects the terpene profile the genetics were selected for in the first place.
These same controls overlap heavily with what a Good Production Practices audit checks for at the facility level. A supplier with a clean GPP record has, by extension, documented the propagation and handling discipline that genetic stability depends on.
Buyers should ask for Certificate of Analysis data across at least three to four consecutive harvests of the same cultivar, not a single report. A tight range across those harvests is a stronger signal than any single high number. For a closer look at what those reports should include, see our guide to terpene profiles for B2B buyers.
Red flags in genetics claims
A few patterns are worth treating with caution during supplier evaluation.
Vague provenance language
Phrases like "exclusive genetics" or "rare phenotype" without any selection history attached are marketing claims, not specifications. Ask for the underlying data.
Single-harvest THC figures used as a permanent spec
A headline cannabinoid percentage from one Certificate of Analysis is a snapshot, not a guarantee. Request the range across multiple harvests before treating a number as a sourcing baseline.
No clear link between propagation method and current stock
If a supplier cannot explain how current production plants trace back to the originally selected phenotype, that is a problem. Genetic drift becomes a real risk over time, even under a stable cultivar name.
AlphaLeaf is a Health Canada Licensed Producer based in Montreal, working with refined genetics and hand-trimmed indoor cultivation under full batch traceability. Our cannabinoid and terpene data is generated through ISO/IEC 17025 accredited testing and held consistent across harvests. We hold export authorisation under the Cannabis Act, supporting supply into international medical and pharmaceutical channels.
Buyers who build genetics questions into procurement end up with supply they can plan around. Relying on a cultivar name alone usually means re-qualifying the supplier every season instead.
Frequently Asked Questions
What is the difference between a cultivar and a strain?
In B2B cannabis sourcing the terms are largely interchangeable, but cultivar is the more precise term for a cultivated genetic line, while strain is the more common consumer-facing word. Procurement documentation should use cultivar.
Can the same cultivar name produce different chemistry from different suppliers?
Yes. Cultivar names are not regulated specifications. Two producers growing a plant under the same name can have selected different phenotypes, so cannabinoid and terpene results can differ meaningfully between suppliers.
How many harvests of data should a buyer request before qualifying a supplier?
Three to four consecutive harvests of the same cultivar gives a buyer a realistic view of batch-to-batch variation, rather than relying on a single best-case Certificate of Analysis.
Does tissue culture propagation guarantee genetic stability?
Tissue culture reduces the genetic drift risk compared with repeated clone generations, but it does not eliminate it on its own. Buyers should still ask how a supplier verifies that current stock matches the originally selected phenotype.
